Shares of Guardian Pharmacy Services, Inc. (NYSE:GRDN – Get Free Report) have earned a consensus rating of “Moderate Buy” from the nine ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation and eight have given a buy recommendation to the company. The average 12-month price target among brokerages that have covered the stock in the last year is $43.8333.
Several equities research analysts have commented on the stock. Truist Financial boosted their target price on shares of Guardian Pharmacy Services from $43.00 to $47.00 and gave the stock a “buy” rating in a research report on Wednesday, June 17th. Wall Street Zen upgraded shares of Guardian Pharmacy Services from a “hold” rating to a “buy” rating in a research note on Sunday, August 9th. Oppenheimer upped their target price on shares of Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research report on Friday, August 7th. Zacks Research downgraded shares of Guardian Pharmacy Services from a “strong-buy” rating to a “hold” rating in a research report on Monday, May 11th. Finally, Weiss Ratings raised Guardian Pharmacy Services from a “hold (c+)” rating to a “buy (b-)” rating in a research note on Thursday, August 20th.
View Our Latest Report on GRDN
Hedge Funds Weigh In On Guardian Pharmacy Services
Guardian Pharmacy Services Trading Up 0.7%
Shares of GRDN stock opened at $37.56 on Thursday. The stock has a 50 day simple moving average of $40.10 and a 200-day simple moving average of $37.86. The company has a market cap of $1.87 billion, a price-to-earnings ratio of 36.47, a price-to-earnings-growth ratio of 1.93 and a beta of 0.10. Guardian Pharmacy Services has a 12-month low of $23.14 and a 12-month high of $47.02.
Guardian Pharmacy Services (NYSE:GRDN – Get Free Report) last posted its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share for the quarter, beating analysts’ consensus estimates of $0.26 by $0.03. The firm had revenue of $351.77 million for the quarter, compared to the consensus estimate of $340.45 million. Guardian Pharmacy Services had a return on equity of 29.97% and a net margin of 4.50%. On average, equities analysts forecast that Guardian Pharmacy Services will post 1.19 earnings per share for the current fiscal year.
Guardian Pharmacy Services Company Profile
Guardian Pharmacy Services, Inc, a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company’s Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs.
Recommended Stories
- Five stocks we like better than Guardian Pharmacy Services
- Williams-Sonoma’s Quarter Gave Bulls More Than Just a Beat-and-Raise
- Alcoa’s Gallium Project Opens a New Door Beyond Aluminum
- Oura’s $16 Billion IPO Could Put a New Price on Wearable Tech
- Can Tesla’s Flying Roadster Distract From Its Real Risks?
Receive News & Ratings for Guardian Pharmacy Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardian Pharmacy Services and related companies with MarketBeat.com's FREE daily email newsletter.
